Keywords: Teva, Cephalon, M&A, European approval, Azilect, USA, FDA review, Parkinson's disease
Teva gets EU clearance for Cephalon acquisition; negative review on Azilect
Article | 14 October 2011
Following US antitrust clearance last week, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) has received approval from the European Commission to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
